GSK PLC-SPON ADR (GSK) Institutional Ownership Changes & 13F Activity

GSK PLC-SPON ADR (GSK) institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC 13F filings (Q1 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions among tracked filers. Notable filers include Dodge & Cox Stock Fund, Renaissance Technologies LLC, Causeway Capital Management, Kahn Brothers Group, and Hillman Value Fund.

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q2 2025Causeway Capital ManagementSell-8471,107,076$42,511,705
Q1 2025Dodge & Cox Stock FundBuy10,210,92178,651,833$3,046,972,010
Q1 2025Renaissance Technologies LLCSell-773,0401,982,153$76,788,607
Q1 2025Hillman Value FundSell-66,008165,143$6,397,640
Q1 2025Causeway Capital ManagementBuy31,3431,107,923$42,920,943
Q1 2025Tweedy, Browne Co All Funds (US)Sell-3,27190,545$3,507,713
Q1 2025Sequoia Financial AdvisorsBuy2,64923,294$902,411
Q4 2024Renaissance Technologies LLCBuy419,7002,755,193$93,180,627
Q4 2024Dodge & Cox Stock FundBuy353,74968,440,912$2,314,671,644
Q4 2024Causeway Capital ManagementBuy179,1741,076,580$36,409,929
Q4 2024Hillman Value FundBuy34,255231,151$7,817,527
Q4 2024Tweedy, Browne Co All Funds (US)Sell-14,21993,816$3,172,857
Q4 2024Sequoia Financial AdvisorsSell-2,29220,645$698,198
Q3 2024Dodge & Cox Stock FundSell-249,97568,087,163$2,783,403,223
Q3 2024Causeway Capital ManagementBuy143,871897,406$36,685,942
Q3 2024Renaissance Technologies LLCSell-12,5002,335,493$95,474,954
Q3 2024Tweedy, Browne Co All Funds (US)Sell-1,820108,035$4,416,471
Q3 2024Hillman Value FundBuy1,770196,896$8,049,108
Q3 2024Sequoia Financial AdvisorsBuy57722,937$937,665
Q2 2024Renaissance Technologies LLCBuy554,6002,347,993$90,397,731
Q2 2024Dodge & Cox Stock FundSell-525,17068,337,138$2,630,979,813
Q2 2024Hillman Value FundSell-38,360195,126$7,512,336
Q2 2024Causeway Capital ManagementBuy16,350753,535$29,011,113
Q2 2024Tweedy, Browne Co All Funds (US)Sell-13,189109,855$4,229,418
Q2 2024Sequoia Financial AdvisorsBuy18322,360$860,854
Q1 2024Renaissance Technologies LLCSell-971,8001,793,393$76,883
Q1 2024Dodge & Cox Stock FundSell-164,48568,862,308$2,952,127,144
Q1 2024Causeway Capital ManagementSell-58,256737,185$31,603,132
Q1 2024Tweedy, Browne Co All Funds (US)Sell-1,356123,044$5,274,896
Q1 2024Sequoia Financial AdvisorsBuy1,00022,177$950,728

Frequently asked questions about GSK activity

  • Which institutional owners are buying GSK?

    Institutional owners buying GSK include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in GSK activity?

    "Buy" means an investor increased their reported position in GSK compared to the prior reporting period. This reflects growing exposure to GSK PLC-SPON ADR (GSK) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in GSK increasing?

    Institutional interest in GSK can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.

Related GSK insights